<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1689">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04416334</url>
  </required_header>
  <id_info>
    <org_study_id>COLCHICOVID</org_study_id>
    <nct_id>NCT04416334</nct_id>
  </id_info>
  <brief_title>PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS</brief_title>
  <acronym>COLCHI-COVID</acronym>
  <official_title>PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS SARS-CoV2 (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Marqués de Valdecilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gerencia de atención primaria área 1</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gerencia de atención primaria área 2</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gerencia Atencion Primaria Area 3</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gerencia de atención primaria área 4</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigación Marqués de Valdecilla</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3 clinical trial, randomized, single-center, opened, controlled, to evaluate&#xD;
      efficacy and safety of early administration of colchicines in patients older than 60 years,&#xD;
      with high risk of pulmonary complications due to coronavirus SARS-CoV2 (COVID-19). An&#xD;
      approximately number of 954 subjects meeting all inclusion and none exclusion criteria will&#xD;
      be randomized either to receive colchicines or symptomatic treatment with paracetamol during&#xD;
      21 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to determine whether short term course of colchicines&#xD;
      reduces number of deaths due to COVID-19 and severe complications due to the virus in elderly&#xD;
      patients with comorbidities.&#xD;
&#xD;
      The secondary objective is to determine the safety of colchicines in this patient population.&#xD;
&#xD;
      Approximately 954 subjects who meet all inclusion criteria and none exclusion criteria will&#xD;
      be randomized either to receive colchicines or symptomatic treatment (2:1 allocation ratio)&#xD;
      during 21 days. Follow-up assessments will occur every 48 hours and always at day 10, 21 and&#xD;
      61 following randomization for evaluation of the occurrence of any trial endpoints or other&#xD;
      adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 25, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who die due to COVID-19 infection</measure>
    <time_frame>21 days post-randomization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who require hospitalization due to COVID-19 infection</measure>
    <time_frame>21 days post-randomization</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>A confirmed diagnosis from COVID-19 infection (by positive PCR test) will be mandatory .</measure>
    <time_frame>48 hours</time_frame>
    <description>not delayed more than 48 hours from initial symptoms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">954</enrollment>
  <condition>SARS-CoV-2 Infection (COVID-19)</condition>
  <arm_group>
    <arm_group_label>Colchicine plus symptomatic treatment (paracetamol).</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive study medication colchicines 0.5 mg orally (PO) twice daily for the first 3 days and then once daily for the last 18 days. If a dose is missed, it should not be replaced.&#xD;
All patients should also receive best symptomatic treatment (mainly paracetamol), based on clinical practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symptomatic treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine plus symptomatic treatment (paracetamol)</intervention_name>
    <description>Colchicine plus symptomatic treatment (paracetamol).</description>
    <arm_group_label>Colchicine plus symptomatic treatment (paracetamol).</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)</intervention_name>
    <description>Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).</description>
    <arm_group_label>Symptomatic treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of both sexes who are at least 60 years old.&#xD;
&#xD;
          2. Diagnosis of COVID-19 infection in the last 72 hours and confirmed by PCR&#xD;
&#xD;
          3. Patient in outpatient follow-up (not hospitalized or under consideration) or&#xD;
             institutionalized in senior centers/residences&#xD;
&#xD;
          4. The patient must possess at least two of the following high-risk criteria&#xD;
&#xD;
               1. 60 years of age or older AND&#xD;
&#xD;
               2. Any of the following: Diabetes mellitus, high blood pressure, known pulmonary&#xD;
                  disease (including asthma or chronic obstructive pulmonary disease), known heart&#xD;
                  failure, known coronary disease, bicytopenia, pancytopenia, or the existence of&#xD;
                  simultaneous neutrophilia and lymphopenia&#xD;
&#xD;
          5. The patient must be able and willing to comply with the requirements of this study&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hospitalized patient or under immediate consideration of doing so&#xD;
&#xD;
          2. Patient taking colchicine for other indications&#xD;
&#xD;
          3. Patient with history of allergic reaction or sensitivity to colchicine&#xD;
&#xD;
          4. Patient with inflammatory bowel disease, gastric ulcer, chronic diarrhea or&#xD;
             malabsorption&#xD;
&#xD;
          5. Patient with pre-existing progressive neuromuscular disease&#xD;
&#xD;
          6. Patient with kidney damage and estimated glomerular filtrate rate &lt;30 ml/m at 1732&#xD;
&#xD;
          7. Patient undergoing chemotherapy for cancer, including haematological malignancies.&#xD;
&#xD;
          8. Patients being treated with CYP3A4 and/or glycoprotein inhibitor drugs&#xD;
&#xD;
          9. Immunosuppressive treatment&#xD;
&#xD;
         10. History of cirrhosis, chronic active hepatitis, severe chronic disease defined by GOT&#xD;
             or GPT values exceeding 3 times the upper limit of normal.&#xD;
&#xD;
         11. If the investigator considers it, for any reason, to be an inadequate candidate.&#xD;
&#xD;
         12. Patient and/or legal representative will not have signed the informed consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carlos Richard</last_name>
    <phone>942203333</phone>
    <email>carlos.richard@scsalud.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mar García, PhD</last_name>
    <phone>942203333</phone>
    <email>mmar.garcia@scsalud.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Atención primaria (Área 2)</name>
      <address>
        <city>Laredo</city>
        <state>Cantabria</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Carlos Lopez Caro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gerencia de atención primaria (Área 3)</name>
      <address>
        <city>Reinosa</city>
        <state>Cantabria</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonatan Diaz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atencion primaria (AREA 1)</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>elena Bustamante</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gerencia de atención primaria (área 4)</name>
      <address>
        <city>Torrelavega</city>
        <state>Cantabria</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Ramon fonfria</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colchicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

